Exvastat Enters COVID-19 Arena With Intravenous Imatinib
Reformulating Cancer Blockbuster For ARDS
The UK firm has tapped into EU funds through an Irish subsidiary to advance its treatment for acute respiratory distress syndrome based on a reformulation of Novartis's Gleevec.
You may also be interested in...
Turnover at the German group's pharma unit has been hit harder than forecast by the coronavirus pandemic and hefty price cuts linked to China's drug procurement policy but Bayer remains upbeat.
The Italian firm's move to license Isturisa from Novartis last year is paying dividends already and Recordati has already tripled its peak sales forecast for the Cushing's therapy.
Novartis is the latest big pharma to sign up for access to Sangamo's gene therapy technologies, inking a deal that will focus on neurodevelopment disorders and could be worth in the region of $800m.